Revenue Recognition and Accounts Receivable Revenue Disaggregation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Net sales	$ 15,388.4	$ 16,218.1	$ 17,813.6
Biocon Biologics
Disaggregation of Revenue [Line Items]
Net sales		601.1	607.3
Brands
Disaggregation of Revenue [Line Items]
Net sales	9,800.5	9,889.6	10,841.3
Generics
Disaggregation of Revenue [Line Items]
Net sales	5,587.9	6,328.5	6,972.3
Net sales
Disaggregation of Revenue [Line Items]
Net sales	15,388.4	16,218.1	17,813.6
Developed Markets | Brands
Disaggregation of Revenue [Line Items]
Net sales	5,239.0	5,160.4	5,759.2
Developed Markets | Generics
Disaggregation of Revenue [Line Items]
Net sales	4,012.9	4,608.5	4,669.5
Greater China | Brands
Disaggregation of Revenue [Line Items]
Net sales	2,152.1	2,190.7	2,207.8
Greater China | Generics
Disaggregation of Revenue [Line Items]
Net sales	8.3	10.5	5.0
JANZ | Brands
Disaggregation of Revenue [Line Items]
Net sales	782.9	922.6	1,197.1
JANZ | Generics
Disaggregation of Revenue [Line Items]
Net sales	641.6	709.8	830.3
Emerging Markets | Brands
Disaggregation of Revenue [Line Items]
Net sales	1,626.5	1,615.9	1,677.2
Emerging Markets | Generics
Disaggregation of Revenue [Line Items]
Net sales	925.1	999.7	1,467.5
Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	15,388.4	16,218.1
Operating Segments | Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	9,251.9	9,768.9	10,428.7
Operating Segments | Greater China
Disaggregation of Revenue [Line Items]
Net sales	2,160.4	2,201.2	2,212.8
Operating Segments | JANZ
Disaggregation of Revenue [Line Items]
Net sales	1,424.5	1,632.4	2,027.4
Operating Segments | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	$ 2,551.6	$ 2,615.6	$ 3,144.7